Drugs interactions for Rinvoq®

  • 205 Major drug interactions (including ingredients like Abametapir, Abatacept, Adalimumab)
  • 105 Moderate drug interactions (including ingredients like Adenovirus type 7 vaccine live, Anthrax immune globulin human, Anthrax vaccine)
  • 36 Minor drug interactions (including ingredients like Allogeneic processed thymus tissue, Amiodarone, Atazanavir)
346 interactions for Rinvoq®
A therapy excluded from this list of known interactions does not necessarily mean that no interactions exist between that therapy and and Rinvoq®.
Abametapir
The serum concentration of Upadacitinib can be increased when it is combined with Abametapir.
Abatacept
The risk or severity of adverse effects can be increased when Abatacept is combined with Upadacitinib.
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Upadacitinib.
Aldesleukin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Upadacitinib.
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Upadacitinib.
Anakinra
The risk or severity of adverse effects can be increased when Anakinra is combined with Upadacitinib.
Anifrolumab
The risk or severity of adverse effects can be increased when Anifrolumab is combined with Upadacitinib.
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Upadacitinib.
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Upadacitinib.
Apremilast
The risk or severity of adverse effects can be increased when Apremilast is combined with Upadacitinib.
Arsenic trioxide
The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Upadacitinib.
Avacincaptad pegol
The risk or severity of adverse effects can be increased when Upadacitinib is combined with Avacincaptad pegol.
Avacopan
The risk or severity of adverse effects can be increased when Avacopan is combined with Upadacitinib.
Azacitidine
The risk or severity of adverse effects can be increased when Azacitidine is combined with Upadacitinib.
Azathioprine
The risk or severity of adverse effects can be increased when Azathioprine is combined with Upadacitinib.
Baricitinib
The risk or severity of adverse effects can be increased when Baricitinib is combined with Upadacitinib.
Basiliximab
The risk or severity of adverse effects can be increased when Basiliximab is combined with Upadacitinib.
Beclomethasone dipropionate
The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Upadacitinib.
Belatacept
The risk or severity of adverse effects can be increased when Belatacept is combined with Upadacitinib.
Belimumab
The risk or severity of adverse effects can be increased when Belimumab is combined with Upadacitinib.
Belinostat
The risk or severity of adverse effects can be increased when Belinostat is combined with Upadacitinib.
Belumosudil
The risk or severity of adverse effects can be increased when Upadacitinib is combined with Belumosudil.
Bendamustine
The risk or severity of adverse effects can be increased when Bendamustine is combined with Upadacitinib.
Betamethasone
The risk or severity of adverse effects can be increased when Betamethasone is combined with Upadacitinib.
Bexarotene
The risk or severity of adverse effects can be increased when Bexarotene is combined with Upadacitinib.
Bimekizumab
The risk or severity of adverse effects can be increased when Bimekizumab is combined with Upadacitinib.
Bleomycin
The risk or severity of adverse effects can be increased when Bleomycin is combined with Upadacitinib.
Blinatumomab
The risk or severity of adverse effects can be increased when Blinatumomab is combined with Upadacitinib.
Bortezomib
The risk or severity of adverse effects can be increased when Bortezomib is combined with Upadacitinib.
Bosutinib
The risk or severity of adverse effects can be increased when Bosutinib is combined with Upadacitinib.
Brentuximab vedotin
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Upadacitinib.
Brodalumab
The risk or severity of adverse effects can be increased when Brodalumab is combined with Upadacitinib.
Budesonide
The risk or severity of adverse effects can be increased when Budesonide is combined with Upadacitinib.
Busulfan
The risk or severity of adverse effects can be increased when Busulfan is combined with Upadacitinib.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Upadacitinib.
Canakinumab
The risk or severity of adverse effects can be increased when Canakinumab is combined with Upadacitinib.
Capecitabine
The risk or severity of adverse effects can be increased when Capecitabine is combined with Upadacitinib.
Carboplatin
The risk or severity of adverse effects can be increased when Carboplatin is combined with Upadacitinib.
Carfilzomib
The risk or severity of adverse effects can be increased when Carfilzomib is combined with Upadacitinib.
Carmustine
The risk or severity of adverse effects can be increased when Carmustine is combined with Upadacitinib.
Certolizumab pegol
The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Upadacitinib.
Chlorambucil
The risk or severity of adverse effects can be increased when Chlorambucil is combined with Upadacitinib.
Chloramphenicol
The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Upadacitinib.
Ciclesonide
The risk or severity of adverse effects can be increased when Ciclesonide is combined with Upadacitinib.
Cisplatin
The risk or severity of adverse effects can be increased when Cisplatin is combined with Upadacitinib.
Clobetasol propionate
The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Upadacitinib.
Clofarabine
The risk or severity of adverse effects can be increased when Clofarabine is combined with Upadacitinib.
Corticotropin
The risk or severity of adverse effects can be increased when Corticotropin is combined with Upadacitinib.
Cortisone acetate
The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Upadacitinib.
Crovalimab
The risk or severity of adverse effects can be increased when Upadacitinib is combined with Crovalimab.
Cyclophosphamide
The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Upadacitinib.
Cyclosporine
Upadacitinib may increase the immunosuppressive activities of Cyclosporine.
Cytarabine
The risk or severity of adverse effects can be increased when Cytarabine is combined with Upadacitinib.
Dacarbazine
The risk or severity of adverse effects can be increased when Dacarbazine is combined with Upadacitinib.
Dactinomycin
The risk or severity of adverse effects can be increased when Dactinomycin is combined with Upadacitinib.
Danicopan
The risk or severity of adverse effects can be increased when Upadacitinib is combined with Danicopan.
Dasatinib
The risk or severity of adverse effects can be increased when Dasatinib is combined with Upadacitinib.
Daunorubicin
The risk or severity of adverse effects can be increased when Daunorubicin is combined with Upadacitinib.
Decitabine
The risk or severity of adverse effects can be increased when Decitabine is combined with Upadacitinib.
Deflazacort
The risk or severity of adverse effects can be increased when Deflazacort is combined with Upadacitinib.
Desoximetasone
The risk or severity of adverse effects can be increased when Desoximetasone is combined with Upadacitinib.
Deucravacitinib
The risk or severity of adverse effects can be increased when Upadacitinib is combined with Deucravacitinib.
Dexrazoxane
The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Upadacitinib.
Dimethyl fumarate
The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Upadacitinib.
Dinutuximab
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Upadacitinib.
Diroximel fumarate
The risk or severity of adverse effects can be increased when Diroximel fumarate is combined with Upadacitinib.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Upadacitinib.
Doxorubicin
The risk or severity of adverse effects can be increased when Doxorubicin is combined with Upadacitinib.
Eculizumab
The risk or severity of adverse effects can be increased when Eculizumab is combined with Upadacitinib.
Efgartigimod alfa
The risk or severity of adverse effects can be increased when Upadacitinib is combined with Efgartigimod alfa.
Emapalumab
The risk or severity of adverse effects can be increased when Emapalumab is combined with Upadacitinib.
Epirubicin
The risk or severity of adverse effects can be increased when Epirubicin is combined with Upadacitinib.
Eribulin
The risk or severity of adverse effects can be increased when Eribulin is combined with Upadacitinib.
Etanercept
The risk or severity of adverse effects can be increased when Etanercept is combined with Upadacitinib.
Etoposide
The risk or severity of adverse effects can be increased when Etoposide is combined with Upadacitinib.
Everolimus
The risk or severity of adverse effects can be increased when Everolimus is combined with Upadacitinib.
Floxuridine
The risk or severity of adverse effects can be increased when Floxuridine is combined with Upadacitinib.
Flucytosine
The risk or severity of adverse effects can be increased when Flucytosine is combined with Upadacitinib.
Fludarabine
The risk or severity of adverse effects can be increased when Fludarabine is combined with Upadacitinib.
Fludrocortisone
The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Upadacitinib.
Flunisolide
The risk or severity of adverse effects can be increased when Flunisolide is combined with Upadacitinib.
Fluocinolone acetonide
The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Upadacitinib.
Fluocinonide
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Upadacitinib.
Fluorometholone
The risk or severity of adverse effects can be increased when Fluorometholone is combined with Upadacitinib.
Fluorouracil
The risk or severity of adverse effects can be increased when Fluorouracil is combined with Upadacitinib.
Fluticasone furoate
The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Upadacitinib.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Upadacitinib.
Gemcitabine
The risk or severity of adverse effects can be increased when Gemcitabine is combined with Upadacitinib.
Gemtuzumab ozogamicin
The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Upadacitinib.
Glatiramer
The risk or severity of adverse effects can be increased when Glatiramer is combined with Upadacitinib.
Golimumab
The risk or severity of adverse effects can be increased when Golimumab is combined with Upadacitinib.
Guselkumab
The risk or severity of adverse effects can be increased when Guselkumab is combined with Upadacitinib.
Hydrocortisone acetate
The risk or severity of adverse effects can be increased when Hydrocortisone acetate is combined with Upadacitinib.
Hydrocortisone butyrate
The risk or severity of adverse effects can be increased when Hydrocortisone butyrate is combined with Upadacitinib.
Hydrocortisone succinate
The risk or severity of adverse effects can be increased when Hydrocortisone succinate is combined with Upadacitinib.
Hydroxychloroquine
The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Upadacitinib.
Hydroxyurea
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Upadacitinib.
Ibritumomab tiuxetan
The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Upadacitinib.
Ibrutinib
The risk or severity of adverse effects can be increased when Ibrutinib is combined with Upadacitinib.
Idarubicin
The risk or severity of adverse effects can be increased when Idarubicin is combined with Upadacitinib.
Idelalisib
The risk or severity of adverse effects can be increased when Idelalisib is combined with Upadacitinib.
Ifosfamide
The risk or severity of adverse effects can be increased when Ifosfamide is combined with Upadacitinib.
Imatinib
The risk or severity of adverse effects can be increased when Imatinib is combined with Upadacitinib.
Indomethacin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Upadacitinib.
Infliximab
The risk or severity of adverse effects can be increased when Infliximab is combined with Upadacitinib.
Interferon alfa-2b
The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Upadacitinib.
Interferon alfa-n3
The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Upadacitinib.
Interferon beta-1b
The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Upadacitinib.
Interferon gamma-1b
The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Upadacitinib.
Iptacopan
The risk or severity of adverse effects can be increased when Upadacitinib is combined with Iptacopan.
Irinotecan
The risk or severity of adverse effects can be increased when Irinotecan is combined with Upadacitinib.
Ixabepilone
The risk or severity of adverse effects can be increased when Ixabepilone is combined with Upadacitinib.
Ixekizumab
The risk or severity of adverse effects can be increased when Ixekizumab is combined with Upadacitinib.
Lenalidomide
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Upadacitinib.
Linezolid
The risk or severity of adverse effects can be increased when Linezolid is combined with Upadacitinib.
Lomustine
The risk or severity of adverse effects can be increased when Lomustine is combined with Upadacitinib.
Mechlorethamine
The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Upadacitinib.
Melphalan
The risk or severity of adverse effects can be increased when Melphalan is combined with Upadacitinib.
Mepolizumab
The risk or severity of adverse effects can be increased when Mepolizumab is combined with Upadacitinib.
Mercaptopurine
The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Upadacitinib.
Methotrexate
The risk or severity of adverse effects can be increased when Methotrexate is combined with Upadacitinib.
Methylprednisolone
The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Upadacitinib.
Mirikizumab
The risk or severity of adverse effects can be increased when Mirikizumab is combined with Upadacitinib.
Mitomycin
The risk or severity of adverse effects can be increased when Mitomycin is combined with Upadacitinib.
Mitoxantrone
The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Upadacitinib.
Mometasone furoate
The risk or severity of adverse effects can be increased when Mometasone furoate is combined with Upadacitinib.
Monomethyl fumarate
The risk or severity of adverse effects can be increased when Monomethyl fumarate is combined with Upadacitinib.
Mosunetuzumab
The risk or severity of adverse effects can be increased when Upadacitinib is combined with Mosunetuzumab.
Mycophenolate mofetil
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Upadacitinib.
Mycophenolic acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Upadacitinib.
Natalizumab
The risk or severity of immunosuppression can be increased when Upadacitinib is combined with Natalizumab.
Nelarabine
The risk or severity of adverse effects can be increased when Nelarabine is combined with Upadacitinib.
Obinutuzumab
The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Upadacitinib.
Ocrelizumab
The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Upadacitinib.
Ofatumumab
The risk or severity of adverse effects can be increased when Ofatumumab is combined with Upadacitinib.
Olaparib
The risk or severity of adverse effects can be increased when Olaparib is combined with Upadacitinib.
Oxaliplatin
The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Upadacitinib.
Ozanimod
The risk or severity of adverse effects can be increased when Ozanimod is combined with Upadacitinib.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Upadacitinib.
Palbociclib
The risk or severity of adverse effects can be increased when Palbociclib is combined with Upadacitinib.
Panobinostat
The risk or severity of adverse effects can be increased when Panobinostat is combined with Upadacitinib.
Pazopanib
The risk or severity of adverse effects can be increased when Pazopanib is combined with Upadacitinib.
Pegaspargase
The risk or severity of adverse effects can be increased when Pegaspargase is combined with Upadacitinib.
Pegcetacoplan
The risk or severity of adverse effects can be increased when Upadacitinib is combined with Pegcetacoplan.
Peginterferon alfa-2a
The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Upadacitinib.
Peginterferon alfa-2b
The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Upadacitinib.
Peginterferon beta-1a
The risk or severity of adverse effects can be increased when Peginterferon beta-1a is combined with Upadacitinib.
Pemetrexed
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Upadacitinib.
Penicillamine
The risk or severity of adverse effects can be increased when Penicillamine is combined with Upadacitinib.
Pentostatin
The risk or severity of adverse effects can be increased when Pentostatin is combined with Upadacitinib.
Phenylalanine
The risk or severity of adverse effects can be increased when Phenylalanine is combined with Upadacitinib.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Upadacitinib.
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Upadacitinib.
Pirtobrutinib
The risk or severity of adverse effects can be increased when Upadacitinib is combined with Pirtobrutinib.
Pomalidomide
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Upadacitinib.
Ponatinib
The risk or severity of adverse effects can be increased when Ponatinib is combined with Upadacitinib.
Ponesimod
The risk or severity of adverse effects can be increased when Ponesimod is combined with Upadacitinib.
Pozelimab
The risk or severity of adverse effects can be increased when Upadacitinib is combined with Pozelimab.
Pralatrexate
The risk or severity of adverse effects can be increased when Pralatrexate is combined with Upadacitinib.
Prednisolone
The risk or severity of adverse effects can be increased when Prednisolone is combined with Upadacitinib.
Prednisone
The risk or severity of adverse effects can be increased when Prednisone is combined with Upadacitinib.
Procarbazine
The risk or severity of adverse effects can be increased when Procarbazine is combined with Upadacitinib.
Propylthiouracil
The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Upadacitinib.
Ravulizumab
The risk or severity of adverse effects can be increased when Ravulizumab is combined with Upadacitinib.
Rilonacept
The risk or severity of adverse effects can be increased when Rilonacept is combined with Upadacitinib.
Risankizumab
The risk or severity of adverse effects can be increased when Risankizumab is combined with Upadacitinib.
Rituximab
The risk or severity of adverse effects can be increased when Rituximab is combined with Upadacitinib.
Ropeginterferon alfa-2b
The risk or severity of adverse effects can be increased when Upadacitinib is combined with Ropeginterferon alfa-2b.
Rozanolixizumab
The risk or severity of adverse effects can be increased when Rozanolixizumab is combined with Upadacitinib.
Ruxolitinib
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Upadacitinib.
Sarilumab
The risk or severity of adverse effects can be increased when Sarilumab is combined with Upadacitinib.
Secukinumab
The risk or severity of adverse effects can be increased when Secukinumab is combined with Upadacitinib.
Siltuximab
The risk or severity of adverse effects can be increased when Siltuximab is combined with Upadacitinib.
Siponimod
The risk or severity of adverse effects can be increased when Siponimod is combined with Upadacitinib.
Sirolimus
The risk or severity of adverse effects can be increased when Sirolimus is combined with Upadacitinib.
Sorafenib
The risk or severity of adverse effects can be increased when Sorafenib is combined with Upadacitinib.
Spesolimab
The risk or severity of adverse effects can be increased when Upadacitinib is combined with Spesolimab.
Streptozocin
The risk or severity of adverse effects can be increased when Streptozocin is combined with Upadacitinib.
Sulfasalazine
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Upadacitinib.
Sunitinib
The risk or severity of adverse effects can be increased when Sunitinib is combined with Upadacitinib.
Sutimlimab
The risk or severity of adverse effects can be increased when Sutimlimab is combined with Upadacitinib.
Temozolomide
The risk or severity of adverse effects can be increased when Temozolomide is combined with Upadacitinib.
Temsirolimus
The risk or severity of adverse effects can be increased when Temsirolimus is combined with Upadacitinib.
Teniposide
The risk or severity of adverse effects can be increased when Teniposide is combined with Upadacitinib.
Teprotumumab
The risk or severity of adverse effects can be increased when Teprotumumab is combined with Upadacitinib.
Teriflunomide
The risk or severity of adverse effects can be increased when Teriflunomide is combined with Upadacitinib.
Thalidomide
The risk or severity of adverse effects can be increased when Thalidomide is combined with Upadacitinib.
Thiotepa
The risk or severity of adverse effects can be increased when Thiotepa is combined with Upadacitinib.
Tioguanine
The risk or severity of adverse effects can be increased when Tioguanine is combined with Upadacitinib.
Tixocortol
The risk or severity of adverse effects can be increased when Tixocortol is combined with Upadacitinib.
Tocilizumab
The risk or severity of adverse effects can be increased when Tocilizumab is combined with Upadacitinib.
Topotecan
The risk or severity of adverse effects can be increased when Topotecan is combined with Upadacitinib.
Trabectedin
The risk or severity of adverse effects can be increased when Trabectedin is combined with Upadacitinib.
Trastuzumab emtansine
The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Upadacitinib.
Triamcinolone
The risk or severity of adverse effects can be increased when Triamcinolone is combined with Upadacitinib.
Trifluridine
The risk or severity of adverse effects can be increased when Trifluridine is combined with Upadacitinib.
Vedolizumab
The risk or severity of adverse effects can be increased when Vedolizumab is combined with Upadacitinib.
Vilanterol
The risk or severity of adverse effects can be increased when Vilanterol is combined with Upadacitinib.
Vinblastine
The risk or severity of adverse effects can be increased when Vinblastine is combined with Upadacitinib.
Vincristine
The risk or severity of adverse effects can be increased when Vincristine is combined with Upadacitinib.
Vinorelbine
The risk or severity of adverse effects can be increased when Vinorelbine is combined with Upadacitinib.
Voclosporin
The risk or severity of adverse effects can be increased when Voclosporin is combined with Upadacitinib.
Vorinostat
The risk or severity of adverse effects can be increased when Vorinostat is combined with Upadacitinib.
Zidovudine
The risk or severity of adverse effects can be increased when Zidovudine is combined with Upadacitinib.
Zilucoplan
The risk or severity of adverse effects can be increased when Upadacitinib is combined with Zilucoplan.
Adenovirus type 7 vaccine live
The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Upadacitinib.
Anthrax immune globulin human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Upadacitinib.
Anthrax vaccine
The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Upadacitinib.
Apalutamide
The metabolism of Upadacitinib can be increased when combined with Apalutamide.
Aprepitant
The metabolism of Upadacitinib can be decreased when combined with Aprepitant.
AstraZeneca COVID-19 Vaccine
The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Upadacitinib.
Avanafil
The serum concentration of Avanafil can be increased when it is combined with Upadacitinib.
Bacillus calmette-guerin substrain tice live antigen
The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Upadacitinib.
Berotralstat
The metabolism of Upadacitinib can be decreased when combined with Berotralstat.
Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)
The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Upadacitinib.
Carbamazepine
The metabolism of Upadacitinib can be increased when combined with Carbamazepine.
Cenobamate
The serum concentration of Upadacitinib can be decreased when it is combined with Cenobamate.
Chikungunya vaccine (live, attenuated)
The therapeutic efficacy of Chikungunya vaccine (live, attenuated) can be decreased when used in combination with Upadacitinib.
Ciprofloxacin
The metabolism of Upadacitinib can be decreased when combined with Ciprofloxacin.
Clostridium tetani toxoid antigen (formaldehyde inactivated)
The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Upadacitinib.
Clozapine
The metabolism of Upadacitinib can be decreased when combined with Clozapine.
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Upadacitinib.
Dabrafenib
The serum concentration of Upadacitinib can be decreased when it is combined with Dabrafenib.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Upadacitinib.
Desvenlafaxine
The metabolism of Upadacitinib can be decreased when combined with Desvenlafaxine.
Dexamethasone
The metabolism of Upadacitinib can be increased when combined with Dexamethasone.
Diltiazem
The metabolism of Upadacitinib can be decreased when combined with Diltiazem.
Dronedarone
The metabolism of Upadacitinib can be decreased when combined with Dronedarone.
Ebola Zaire vaccine (live, attenuated)
The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Upadacitinib.
Elasomeran
The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Upadacitinib.
Enzalutamide
The metabolism of Upadacitinib can be increased when combined with Enzalutamide.
Epcoritamab
The serum concentration of Upadacitinib can be increased when it is combined with Epcoritamab.
Erythromycin
The serum concentration of Upadacitinib can be increased when it is combined with Erythromycin.
Etrasimod
The risk or severity of immunosuppression can be increased when Upadacitinib is combined with Etrasimod.
Fedratinib
The serum concentration of Upadacitinib can be increased when it is combined with Fedratinib.
Fingolimod
Upadacitinib may increase the immunosuppressive activities of Fingolimod.
Fluconazole
The metabolism of Upadacitinib can be decreased when combined with Fluconazole.
Fluvoxamine
The metabolism of Upadacitinib can be decreased when combined with Fluvoxamine.
Fosnetupitant
The metabolism of Upadacitinib can be decreased when combined with Fosnetupitant.
Fosphenytoin
The metabolism of Upadacitinib can be increased when combined with Fosphenytoin.
Fusidic acid
The metabolism of Upadacitinib can be decreased when combined with Fusidic acid.
Glofitamab
The serum concentration of Upadacitinib can be increased when it is combined with Glofitamab.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Upadacitinib.
Haloperidol
The serum concentration of Haloperidol can be increased when it is combined with Upadacitinib.
Hepatitis A Vaccine
The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Upadacitinib.
Hepatitis B Vaccine (Recombinant)
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Upadacitinib.
Human adenovirus e serotype 4 strain cl-68578 antigen
The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Upadacitinib.
Isavuconazonium
The metabolism of Upadacitinib can be decreased when combined with Isavuconazonium.
Isoniazid
The metabolism of Upadacitinib can be decreased when combined with Isoniazid.
Isradipine
The metabolism of Upadacitinib can be decreased when combined with Isradipine.
Ivacaftor
The serum concentration of Upadacitinib can be increased when it is combined with Ivacaftor.
Ivosidenib
The metabolism of Upadacitinib can be increased when combined with Ivosidenib.
Janssen COVID-19 Vaccine
The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Upadacitinib.
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)
The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Upadacitinib.
Leflunomide
The risk or severity of adverse effects can be increased when Upadacitinib is combined with Leflunomide.
Linagliptin
The metabolism of Upadacitinib can be decreased when combined with Linagliptin.
Lopinavir
The serum concentration of Upadacitinib can be increased when it is combined with Lopinavir.
Lumacaftor
The metabolism of Upadacitinib can be increased when combined with Lumacaftor.
Magnesium
The serum concentration of Magnesium can be decreased when it is combined with Upadacitinib.
Mavacamten
The serum concentration of Upadacitinib can be decreased when it is combined with Mavacamten.
Measles virus vaccine live attenuated
The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Upadacitinib.
Miconazole
The metabolism of Upadacitinib can be decreased when combined with Miconazole.
Midostaurin
The metabolism of Upadacitinib can be increased when combined with Midostaurin.
Milnacipran
The metabolism of Upadacitinib can be decreased when combined with Milnacipran.
Mitotane
The metabolism of Upadacitinib can be increased when combined with Mitotane.
Modified vaccinia ankara
The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Upadacitinib.
mRNA-1345
The therapeutic efficacy of mRNA-1345 can be decreased when used in combination with Upadacitinib.
Mumps virus strain B level jeryl lynn live antigen
The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Upadacitinib.
Netupitant
The metabolism of Upadacitinib can be decreased when combined with Netupitant.
Nicardipine
The metabolism of Upadacitinib can be decreased when combined with Nicardipine.
Nuvaxovid
The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Upadacitinib.
Pentobarbital
The metabolism of Upadacitinib can be increased when combined with Pentobarbital.
Phenobarbital
The metabolism of Upadacitinib can be increased when combined with Phenobarbital.
Phenytoin
The metabolism of Upadacitinib can be increased when combined with Phenytoin.
Pitolisant
The serum concentration of Upadacitinib can be decreased when it is combined with Pitolisant.
Primaquine
The metabolism of Upadacitinib can be decreased when combined with Primaquine.
Primidone
The metabolism of Upadacitinib can be increased when combined with Primidone.
Rabies immune globulin, human
The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Upadacitinib.
Rabies virus inactivated antigen, A
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Upadacitinib.
Rabies virus inactivated antigen, B
The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Upadacitinib.
Respiratory syncytial virus vaccine, adjuvanted
The therapeutic efficacy of GSK-3844766A can be decreased when used in combination with Upadacitinib.
Rifampin
The metabolism of Upadacitinib can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Upadacitinib can be increased when combined with Rifapentine.
Ritlecitinib
The serum concentration of Upadacitinib can be increased when it is combined with Ritlecitinib.
Ritonavir
The serum concentration of Upadacitinib can be increased when it is combined with Ritonavir.
Rotavirus vaccine
The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Upadacitinib.
Rubella virus vaccine
The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Upadacitinib.
Satralizumab
The serum concentration of Upadacitinib can be decreased when it is combined with Satralizumab.
Sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Upadacitinib.
Smallpox (Vaccinia) Vaccine, Live
The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Upadacitinib.
Sotorasib
The serum concentration of Upadacitinib can be decreased when it is combined with Sotorasib.
Stiripentol
The metabolism of Upadacitinib can be decreased when combined with Stiripentol.
Sulfamethoxazole
The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Upadacitinib.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Upadacitinib.
Telotristat ethyl
The serum concentration of Upadacitinib can be decreased when it is combined with Telotristat ethyl.
Tick-borne encephalitis vaccine (whole virus, inactivated)
The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Upadacitinib.
Tofacitinib
Upadacitinib may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab
The risk or severity of neutropenia can be increased when Trastuzumab is combined with Upadacitinib.
Tucatinib
The metabolism of Tucatinib can be decreased when combined with Upadacitinib.
Typhoid vaccine
The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Upadacitinib.
Typhoid Vaccine Live
The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Upadacitinib.
Typhoid Vi polysaccharide vaccine
The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Upadacitinib.
Ublituximab
The risk or severity of infection can be increased when Ublituximab is combined with Upadacitinib.
Varicella zoster vaccine (live/attenuated)
The therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Upadacitinib.
Varicella zoster vaccine (recombinant)
The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Upadacitinib.
Venetoclax
The metabolism of Upadacitinib can be decreased when combined with Venetoclax.
Verapamil
The metabolism of Upadacitinib can be decreased when combined with Verapamil.
Vibrio cholerae CVD 103-HgR strain live antigen
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Upadacitinib.
Yellow fever vaccine
The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Upadacitinib.
Ziprasidone
The metabolism of Upadacitinib can be decreased when combined with Ziprasidone.
Allogeneic processed thymus tissue
The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Upadacitinib.
Amiodarone
The metabolism of Upadacitinib can be decreased when combined with Amiodarone.
Atazanavir
The metabolism of Upadacitinib can be decreased when combined with Atazanavir.
Cladribine
Upadacitinib may increase the immunosuppressive activities of Cladribine.
Clarithromycin
The metabolism of Upadacitinib can be decreased when combined with Clarithromycin.
Conivaptan
The metabolism of Upadacitinib can be decreased when combined with Conivaptan.
Curcumin
The metabolism of Upadacitinib can be decreased when combined with Curcumin.
Danazol
The metabolism of Upadacitinib can be decreased when combined with Danazol.
Darunavir
The metabolism of Upadacitinib can be decreased when combined with Darunavir.
Econazole
The metabolism of Upadacitinib can be decreased when combined with Econazole.
Efavirenz
The metabolism of Upadacitinib can be decreased when combined with Efavirenz.
Elvitegravir
The metabolism of Upadacitinib can be decreased when combined with Elvitegravir.
Ergotamine
The metabolism of Upadacitinib can be decreased when combined with Ergotamine.
Indinavir
The metabolism of Upadacitinib can be decreased when combined with Indinavir.
Inebilizumab
The risk or severity of infection can be increased when Upadacitinib is combined with Inebilizumab.
Itraconazole
The metabolism of Upadacitinib can be decreased when combined with Itraconazole.
Ketoconazole
The metabolism of Upadacitinib can be decreased when combined with Ketoconazole.
Levoketoconazole
The metabolism of Upadacitinib can be decreased when combined with Levoketoconazole.
Lonafarnib
The metabolism of Upadacitinib can be decreased when combined with Lonafarnib.
Methimazole
The metabolism of Upadacitinib can be decreased when combined with Methimazole.
Metreleptin
The metabolism of Upadacitinib can be increased when combined with Metreleptin.
Nefazodone
The metabolism of Upadacitinib can be decreased when combined with Nefazodone.
Nelfinavir
The metabolism of Upadacitinib can be decreased when combined with Nelfinavir.
Nilotinib
The metabolism of Upadacitinib can be decreased when combined with Nilotinib.
Omaveloxolone
The serum concentration of Upadacitinib can be decreased when it is combined with Omaveloxolone.
Posaconazole
The metabolism of Upadacitinib can be decreased when combined with Posaconazole.
Ribociclib
The metabolism of Upadacitinib can be decreased when combined with Ribociclib.
Rilzabrutinib
The metabolism of Upadacitinib can be decreased when combined with Rilzabrutinib.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Upadacitinib.
Saquinavir
The metabolism of Upadacitinib can be decreased when combined with Saquinavir.
Somatrogon
The metabolism of Upadacitinib can be increased when combined with Somatrogon.
Telithromycin
The metabolism of Upadacitinib can be decreased when combined with Telithromycin.
Tipranavir
The metabolism of Upadacitinib can be decreased when combined with Tipranavir.
Vadadustat
The serum concentration of Upadacitinib can be increased when it is combined with Vadadustat.
Viloxazine
The metabolism of Upadacitinib can be decreased when combined with Viloxazine.
Voriconazole
The metabolism of Upadacitinib can be decreased when combined with Voriconazole.